Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels
Association Between Fecal Microbiota Composition, Metabolite Concentrations, and Indoxyl Sulfate Levels in Hemodialysis Patients
Tungs' Taichung Metroharbour Hospital
60 participants
Apr 1, 2025
OBSERVATIONAL
Conditions
Summary
Gut dysbiosis is frequently characterized by decreased microbial diversity and alterations in the abundance of certain microbial species. In individuals with chronic kidney disease (CKD), dysbiosis and metabolic imbalances are prevalent, contributing to the buildup of gut-derived retention solutes and metabolites in the bloodstream. Research has consistently shown that CKD patients exhibit lower levels of beneficial gut bacteria. However, the specific functional changes in gut microbiota and their interactions with levels of uremic toxins in hemodialysis (HD) patients remain incompletely understood. This study seeks to explore the association of fecal metagenomics and targeted metabolomics in a cohort of 60 patients with different levels of to characterize the complex interplay between the gut microbiome and fecal and serum metabolites.
Eligibility
Inclusion Criteria3
- age 18-80 years and
- diagnosed with CKD stage V
- currently receiving hemodialysis treatment>3 months
Exclusion Criteria13
- pregnant or nursing women
- patients with kidney transplant
- severe infections
- severe cardiac diseases
- liver diseases
- malignancy
- autoimmune disorders
- severe malnutrition
- consumed any type of pre-or probiotics
- had antibiotic therapy within 1 month
- diagnosed irritable bowel syndrome
- Crohn's disease
- ulcerative colitis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06877585